COPD refers to a cluster of diseases (including. The Breathlessness, Cough, and Sputum Scale*

Size: px
Start display at page:

Download "COPD refers to a cluster of diseases (including. The Breathlessness, Cough, and Sputum Scale*"

Transcription

1 The Breathlessness, Cough, and Sputum Scale* The Development of Empirically Based Guidelines for Interpretation Nancy Kline Leidy, PhD; Stephen I. Rennard, MD, FCCP; Jordana Schmier, MA; M. Kathryn C. Jones, MA, MSc; and Mitch Goldman, MD, PhD Background: A patient report of respiratory symptoms in COPD is essential to successfully monitoring disease, adjusting treatment, and evaluating outcomes. Objective: To develop empirically based guidelines for interpreting mean changes in symptom scores using the Breathlessness, Cough, and Sputum Scale (BCSS). Methods: Analyses were performed on data from three multinational trials (n 2,971). Mean changes in BCSS score with treatment were examined by physician and patient ratings of treatment efficacy, juxtaposed with percentage change in symptoms, statistical effect size (ES), FEV 1, and change in St. George Respiratory Questionnaire (SGRQ) score. BCSS scores during an exacerbation were examined relative to changes in peak expiratory flow and rescue medication use. Results: Mean baseline BCSS total score was 5.2 2( SD); 90% of scores were between 2 and 9. Highly efficacious treatment (n 257; physician rating) was associated with a BCSS total score of , representing a 24% improvement (ES 0.7), and corresponding to a 10% improvement in FEV 1 and SGRQ score total of Similar changes in BCSS score were observed during recovery from an exacerbation (n 713; ). Mean change with moderately efficacious treatment (n 965) was , a 13% improvement (ES 0.3) corresponding to SGRQ total score of Mildly efficacious treatment (n 891) was associated with a change of 0.35, a 7% improvement (ES 0.18), with a FEV 1 <1% and SGRQ total score of Conclusions: Patient-reported daily symptom data are sensitive to change and useful for both observational studies and controlled clinical trials of patients with COPD. A mean BCSS total score > 1.0 represents substantial symptomatic improvement, changes of approximately 0.6 can be interpreted as moderate, and changes of 0.3 can be considered small. (CHEST 2003; 124: ) Key words: bronchitis; clinical trials; COPD; cough; dyspnea; emphysema; exacerbation; health-related quality of life; instrument; patient-reported outcome; sputum; St. George Respiratory Questionnaire; symptoms Abbreviations: BCSS Breathlessness, Cough, and Sputum Scale; ES effect size; HRQL health-related quality of life; Mb baseline mean value; Mt treatment mean value; b baseline variance in Breathlessness, Cough, and Sputum Scale score; PEF peak expiratory flow; SGRQ St. George Respiratory Questionnaire COPD refers to a cluster of diseases (including chronic bronchitis and emphysema) characterized by progressive reduction in expiratory airflow with increasing breathlessness, and often with cough, and sputum production. 1 Consensus statements published by the Global Initiative for Chronic Obstructive Lung Disease, 1 as well as the European Respiratory Society, 2 the American Thoracic Society, 3 and the British Thoracic Society, 4 emphasize the importance of assessing these symptoms, in addition to spirometry, in the diagnosis of COPD. Although pulmonary function is an important objective marker of the degree of airflow limitation, the patient s report of symptom severity is an independent measure essential to successfully monitor disease activity, adjust treatment, and evaluate outcomes of care. 1 There are relatively few instruments to assess the severity of respiratory symptoms and symptom outcomes in the COPD population within the context of a clinical trial. The Baseline Dyspnea Index/Transition Dyspnea Index, 5 modified Medical Research Council Dyspnea Scale, 6 Oxygen Cost Diagram, 7 and 2182 Clinical Investigations

2 Borg Scale 8 have been used to evaluate breathlessness but do not address cough or sputum. The length and 3-month recall period of the chronic lung disease severity index 9 is not conducive to evaluating treatment outcomes in controlled clinical trials. Condition-specific health-related quality of life (HRQL) measures, such as the St. George Respiratory Questionnaire (SGRQ) 10 or the Chronic Respiratory Questionnaire, 11 were not designed to assess symptom severity per se, but rather the impact of symptoms on daily functioning and well-being. None of these measures prospectively assess the severity or variability of symptoms day to day. In fact, as of this date, there are no published, validated (reliable, valid, responsive) measures to assess day-to-day symptom severity in COPD. The Breathlessness, Cough, and Sputum Scale (BCSS) was developed to meet the need for a precise, easy-to-use instrument for tracking the severity of respiratory symptoms and evaluating efficacy of treatment in clinical trials of patients with COPD. Designed as part of a daily diary, subjects are asked to assess and record the severity of three symptoms of COPD: breathlessness, cough, and sputum. The diary format of the BCSS enables investigators, and potentially clinicians, to assess symptom variability, including the variance associated with acute exacerbations, and to evaluate the trajectory of symptom severity over time in this patient population. The symptoms of breathlessness, cough, and sputum have been identified as cardinal symptoms of COPD in various consensus statements, 1 4 and are those most likely to be affected by pharmacotherapy designed to ameliorate and control respiratory symptoms in this population. The BCSS is a brief, three-item, patient-reported outcome measure in which each of the three symptoms assessed by the measure is represented by a single item (see Appendix). Patients are asked to evaluate each symptom/item on a 5-point Likert-type scale, ranging from 0 to 4, with higher scores indicating a more severe manifestation of the symptom. *From MEDTAP International (Dr. Leidy and Ms. Schmier), Bethesda, MD; University of Nebraska Medical Center (Dr. Rennard), Omaha, NE; and AstraZeneca (Dr. Goldman and Ms. Jones), Wilmington, DE. This study was supported by AstraZeneca Pharmaceuticals LP. Dr. Jones and Dr. Goldman are employees of AstraZeneca. Dr. Rennard has received research grant support, honoraria for speaking, and fees for consultancy from AstraZeneca. Neither he nor his family have any ownership position in AstraZeneca. Manuscript received October 15, 2002; revision accepted July 23, Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( permissions@chestnet.org). Correspondence to: Nancy Kline Leidy, PhD, Center for Health Outcomes Research, MEDTAP International, Inc., 7101 Wisconsin Ave, Suite 600, Bethesda, MD 20814; leidy@medtap.com A daily total score is expressed as the sum of three item scores, with a range of 0 to 12. For greater precision as a clinical trial outcome, weekly and period (eg, baseline, treatment, follow-up) scores can be computed by aggregating daily scores over time. Results of a previous investigation 12 provided evidence that the BCSS is a reliable and valid measure of symptom severity. Item and total scale scores were found to be internally consistent (Cronbach 0.70 daily; 0.95 to 0.99 over time) and reproducible under stable conditions, in this case, a situation in which both the physician and patient agreed that the treatment produced no change or was mildly effective. Intraclass correlation coefficients for item and total scores ranged from 0.74 to Values for both indicators of reliability exceeded the guideline of 0.70 for group-level analyses. 13 The study also provided evidence of the concurrent, convergent, divergent, and discriminant validity of the BCSS. The previous investigation 12 also indicated the instrument is responsive to change, with preliminary tests suggesting a mean decline of 1 point on the BCSS total scale signifies a substantial reduction in symptom severity. Mean score changes considered small (minimal) to moderate and changes observed during the course of an acute exacerbation of COPD have not yet been determined. The purpose of this study was to evaluate the magnitude of mean change scores observed in the BCSS under various scenarios and develop empirically based guidelines for interpreting results of clinical trials and observational or naturalistic studies in which this instrument is used. Design Materials and Methods Secondary analyses were performed on available, blinded data from 3,643 patients undergoing treatment during the course of three phase-iiia, multicenter, multinational, randomized, double-blind, placebo-controlled clinical trials evaluating the safety and efficacy of sibenadet, a novel dual-dopamine D 2 receptor/ 2 adrenoreceptor agonist developed to treat bronchoconstriction and ameliorate respiratory symptoms in patients with COPD 14,15 ; two of the trials involved a 12-week treatment period (n 2,440), and the third trial was 26 weeks in length (n 1,203). 15 The statistical analysis plan for the secondary analysis was developed by the authors based on the study protocols before receiving the data, and all analyses were performed across treatment groups. Study Subjects All patients were between 35 years and 80 years of age with a history of COPD 2 years, a smoking history, and a percentage of predicted FEV 1 between 20% and 70%. Exclusion criteria included a complicating comorbid condition or need for domiciliary oxygen CHEST / 124 / 6/ DECEMBER,

3 Measures In these trials, the BCSS was administered as a daily diary, yielding multiple assessments over time for each subject. Consistent with its use in clinical trials 14,15 and the validation study, 12 daily scores for each patient were aggregated over the baseline period and again over the final 4 weeks of treatment, defined by the end of study or study discontinuation. Unless otherwise specified, change scores reflect the difference between these two values. In addition to the BCSS, physician and patient ratings of treatment efficacy at the end of the study, FEV 1, SGRQ scores, evening peak flow (PEF) [available in two of the three studies], rescue medication use, and physician-determined severity of the first exacerbation during the study period were used in the analyses. Physician and patient ratings of treatment efficacy were appraised on a 5-point scale, from highly effective to made condition worse. The SGRQ is a widely-used, condition-specific measure of health status or HRQL. 10 Scores range from 0 to 100, with higher scores indicating poorer health status. Guidelines for interpretation suggest changes in the SGRQ total score of 4 points are clinically meaningful, 8 are considered moderate, while 12 are interpreted as a large change in health status. 16 For the subgroup of patients experiencing at least one exacerbation during the study period, symptom severity (BCSS), PEF, and rescue medication use prior to, during, and immediately following the first exacerbation were examined for the subgroup as a whole and by physician-defined severity of exacerbation (mild, moderate, severe). COPD exacerbations were defined as worsening symptoms of COPD requiring drug therapy in addition to study drug, rescue medication, and doses of concomitant COPD medications. 14 Analytical Approach Analyses were performed across treatment groups using aggregated data from the three clinical trials. A triangulation approach was used, where mean score changes on the BCSS were examined in light of mean changes observed in related, commonly used clinical parameters and statistical indicators of magnitude. The following clinical parameters were used in this study: patient and physician ratings of treatment efficacy, FEV 1, SGRQ score, presence of an exacerbation, and PEF and rescue medication use during an exacerbation. Percentage change and effect size (ES) served as statistical indicators. The analytical procedures were as follows. First, three different methods were used to stratify the data into five groups based on ratings of treatment efficacy: highly effective, moderately effective, mildly effective, not effective, and condition made worse. The three rating methods were physician rating of treatment efficacy, patient rating of treatment efficacy, and convergence of physician and patient ratings, that is, the subgroup of patients for whom both the physician and the patient agreed on their ratings of treatment efficacy. The purpose of this procedure was to provide insight into the magnitude of BCSS score changes associated with various levels of treatment efficacy as perceived by physicians and patients. Although the stratification process reduced the effective sample size from the 3,643 randomized patients to 2,971 patients, due to the availability of ratings data as well as complete data on all clinical parameters, the relatively large sample sizes in four of the five efficacy subgroups (n 195 to n 1,063) engendered confidence in the stability of the parameter estimates. Results for the subgroup of patients rated worse should be considered preliminary due to relatively small sample sizes (n 24 to n 62). Because this study was designed to develop interpretation guidelines, ie, to assign meaning to change scores rather than to test the statistical significance of change, only one series of statistical tests was performed at this step in the analyses. Paired t tests were used to confirm that any changes in BCSS score observed in the smaller, not effective groups were not significantly different from zero. The statistical significance of change observed in the remaining groups was not relevant to the purposes of this study. Second, the mean BCSS total and item change scores, stratified by level of treatment efficacy using the three methods outlined above, were juxtaposed with percentage change in symptom severity, statistical ES, FEV 1, and SGRQ score. ES estimates were computed by subtracting the baseline mean value (Mb) from the treatment mean value (Mt) and dividing by the baseline variance in BCSS score ( b) [ES Mt Mb/ b], and were interpreted as follows: values at or near 0.10 were considered small, values at or near 0.30 were regarded as moderate, and values near or 0.50 were interpreted as large. 17 Changes in SGRQ score were evaluated in light of recommended guidelines for the measure as outlined above. 16 Percentage change and FEV 1 provided further clinical context for the interpretation of changes in BCSS score. Finally, to further evaluate the meaning associated with BCSS scores under conditions of known change in the patient s clinical condition, scores during the 7 days preceding a physiciandocumented exacerbation, the first 7 days of the exacerbation, and the first 7 days following medically confirmed resolution were also examined. First, mean daily scores were computed across patients and exhibited graphically, to note the daily patterns of symptom change during this period. Mean values were then computed for each of the three time periods, consistent with the principal of data aggregation over time used in clinical trials. These mean values were then juxtaposed with data on percentage BCSS score, ES, and available data on PEF and rescue medication use during these time periods. The BCSS was also tested for sensitivity to change under this clinical condition using repeated-measures analyses of variance. PEF and rescue medication use were subjected to the same statistical tests to confirm that the three parameters were all moving in the same direction, ie, reflected expected changes in the clinical condition of these patients. Finally, Spearman rank-correlation coefficients (rs) were used to evaluate the consistency of patient ranking based on the magnitude of changes in BCSS score, PEF, and rescue medication use during exacerbations. Results Of the 3,643 patients enrolled in the three trials, 2,971 patients were eligible for these secondary analyses based on the existence of data necessary for the analyses outlined above. Within this group, 1,348 patients had an exacerbation during the course of the trial, of whom 713 patients had BCSS data for use in these analyses. Demographic and clinical characteristics of the analytical sample are provided in Table 1. Mean baseline BCSS total score for the sample was on the 12-point scale (mean SD), with 90% of the sample scoring between 2 and 9). Triangulation results for the BCSS total and item scores for patients with complete data on all indicators are provided in Tables 2, 3. Treatment considered highly efficacious was associated with mean BCSS total score 1.0, which corresponded to 20% improvement in symptoms and an ES 2184 Clinical Investigations

4 Table 1 Sample Demographic and Clinical Characteristics* Characteristics Data Sample size, No. 2,971 Male gender 2,224 (75) Mean age, yr White race 2,936 (98.8) Smoking history, pack-years Pulmonary function FEV 1,L FEV 1 % predicted FVC, L FEV 1 /FVC Exacerbations 1 1,348 (45) Complete BCSS data for analysis 713 (53) *Data are presented as mean SD or No. (%) unless otherwise indicated. With data suitable for secondary analysis. Physician-identified exacerbation of COPD. 0.60, exceeding the 0.50 value considered large. Highly effective treatment was also associated with a SGRQ total score greater than the 8-point change regarded as a moderate change in health status, and an 8 to 10% improvement in FEV 1. For patients in whom treatment was considered moderately efficacious, a mean BCSS total score of at least 0.60 was observed, corresponding to 10% improvement in symptoms and an ES of at least 0.30, considered moderate. Mean SGRQ total score exceeded the 4-point guideline for meaningful improvement in health status, while FEV 1 improved by approximately 5%. Finally, mean BCSS total score associated with treatment considered mildly effective was approximately 0.35, representing a6to 7% improvement in symptoms and an ES nearing 0.20, larger than the 0.10 regarded as small. In this case, mean SGRQ score was less than the 4-point guideline for minimal change, with no change in FEV 1. Mean BCSS total score did not change in the subgroup of patients for whom the treatment was considered ineffective (t 0.12, p 0.90 for physician rating of treatment efficacy; t 1.89, p 0.06 for patient rating of treatment efficacy; and t 1.47, p 0.14, for the subgroup of patients and physicians who concurred on their efficacy ratings). Mean changes in the three items comprising the BCSS are shown in Table 3. Because of the consistency in results across the three methods, only results for physician ratings of treatment efficacy are shown. Change scores for SGRQ subscales are provided to further aid in the interpretation process. Breathlessness, cough, and sputum scores for treatment considered highly effective changed by an average of 0.56, 0.40, and 0.30, respectively, from baseline to the end of treatment. These changes reflected 20% improvement in each of the three symptoms and ESs of 0.79 (breathlessness, large), 0.52 (cough, moderate to large), and 0.37 (sputum, moderate). Concomitant FEV 1 and SGRQ score are provided in Table 2. Mean daily BCSS total scores over time for the exacerbation period by severity of exacerbation are shown in Figure 1. Mean values for each of the three arbitrarily defined phases of exacerbation and mean change over time are shown in Table 4. As expected, there were significant time and severity-by-time interaction effects for the BCSS total score (p ). Rescue medication use also showed a significant time (p ) and severity-by-time interaction (p 0.001). Mean BCSS scores for periods of symptomatic decline (1.24, 24% deterioration) and recovery ( 1.28, 20% improvement) were similar to those observed with highly effective treatment. PEF data (n 448) showed a 4% decline and 5% improvement during deterioration and recovery, respectively. As one might expect, the most remarkable symptomatic improvements were seen in patients recovering from a severe exacerbation, where a mean BCSS total score of 1.81 was observed (n 99), with a parallel (24%) decline in rescue medication use (n 69). The individual item scores deteriorated an average of for breathlessness, for cough, and points for sputum; with recovery, scores improved by , , and for the three symptoms, respectively. There was a statistically significant correspondence between BCSS score and change in both PEF and rescue medication use during the course of the exacerbation (p ). As peak flow declined, BCSS total score increased (symptoms became more severe; rs 0.51). Correlations between PEF and the three symptoms comprising the BCSS were 0.44, 0.46, and 0.45 for breathlessness, cough, and sputum, respectively. Similarly, as BCSS scores increased, there was a concomitant increase in rescue medication use (rs 0.37 for the total score; rs 0.40, rs 0.30, and rs 0.27 for breathlessness, cough, and sputum, respectively). During the recovery period, BCSS scores (symptoms) improved as PEF improved (rs 0.47 for the total score; rs 0.45, rs 0.34, and rs 0.36 for breathlessness, cough, and sputum, respectively) and rescue medication use declined (rs 0.39 for the total score; rs 0.40, rs 0.29, and rs 0.29 for breathlessness, cough, and sputum, respectively). CHEST / 124 / 6/ DECEMBER,

5 Table 2 Change From Baseline to End of Study in Mean BCSS Total Score by Physician and Patient Ratings of Treatment Efficacy Juxtaposed With Mean SGRQ Total Score and FEV 1 Physician (n 2,971) Patient (n 2,272) Physician and Patient* (n 1,887) Efficacy Rating BCSS Total SGRQ Total FEV 1,L BCSS Total SGRQ Total FEV 1,L BCSS Total SGRQ Total FEV 1,L Highly effective Mean (SD) 1.26 (1.81) (13.82) 0.14 (0.39) 1.13 (1.85) 9.78 (13.05) 0.11 (0.34) 1.36 (1.82) (14.16) 0.15 (0.39) No Change, % ES Moderately effective Mean (SD) 0.67 (1.82) 6.80 (12.59) 0.08 (0.31) 0.60 (1.79) 6.35 (12.39) 0.06 (0.31) 0.63 (1.78) 7.06 (12.77) 0.08 (0.32) No Change, % ES Mildly effective Mean (SD) 0.36 (1.74) 2.56 (11.73) 0.01 (0.25) 0.33 (1.69) 1.39 (11.07) 0.00 (0.25) 0.37 (1.75) 1.26 (11.69) 0.00 (0.26) No Change, % ES Not effective Mean (SD) 0.01 (1.65) 0.67 (10.78) 0.02 (0.23) 0.12 (1.64) 1.44 (10.64) 0.01 (0.24) 0.11 (1.62) 1.65 (10.46) 0.01 (0.24) No Change, % ES Made worse Mean (SD) 0.25 (1.81) 5.05 (9.34) 0.05 (0.21) 0.11 (1.84) 6.48 (11.78) 6.48 (11.78) 0.53 (1.89) 5.81 (9.62) 0.06 (0.18) No Change, % ES *Subgroup in which physicians and patients concurred on treatment efficacy. ES (Mt Mb)/ b Clinical Investigations

6 Table 3 Change From Baseline to End of Study in Mean BCSS Item Scores by Physician Rating of Treatment Efficacy, Juxtaposed With Mean Change in SGRQ Subscale Scores BCSS Items SGRQ Subscales Efficacy Rating* Breathlessness Cough Sputum Symptoms Activities Impacts Highly Effective Mean (SD) 0.56 (0.70) 0.40 (0.73) 0.30 (0.76) (20.49) 9.01 (17.00) 9.46 (16.34) No Change, % ES Moderately effective Mean (SD) 0.35 (0.71) 0.20 (0.75) 0.11 (0.72) 9.88 (19.80) 5.89 (15.04) 6.35 (14.78) No Change, % ES Mildly effective Mean (SD) 0.21 (0.69) 0.13 (0.72) 0.02 (0.72) 5.27 (19.18) 1.99 (14.36) 1.95 (14.24) No Change, % ES Not effective Mean (SD) 0.05 (0.66) 0.03 (0.70) 0.08 (0.69) 1.46 (19.84) 0.42 (13.45) 1.54 (13.05) No Change, % ES Made Worse Mean (SD) 0.02 (0.67) 0.11 (0.72) 0.16 (0.75) 5.98 (16.99) 4.44 (14.39) 5.06 (10.54) No Change, % ES *ES (Mt Mb)/ b. Discussion The purpose of this study was to develop guidelines for interpreting group-level changes in BCSS scores in clinical studies of COPD. A triangulation method was used, juxtaposing BCSS change scores by clinical indicators of treatment success commonly used in clinical practice and trials involving patients with COPD (physician and patient perception of treatment efficacy, FEV 1, and SGRQ scores) along with statistical indicators of magnitude (percentage change and ES). Daily and weekly BCSS scores were also examined under conditions of known change, that is, from the period immediately prior to a medically confirmed exacerbation to the first 7 days of the exacerbation period, and the first 7 days following physician determined resolution. In this case, BCSS scores were examined in light of two objective clinical measures commonly used to evaluate treatment success under these conditions (PEF and rescue medication use), as well as the statistical indicators of magnitude. It is important to note that this study was a secondary analysis of an existing data set, rather than a prospective study of change. In order to fully utilize the available data without bias, a comprehensive statistical analysis plan was developed by investigators who did not develop the instrument and who were blind to the data at the time the plan was written (N.K.L., J.S.). These investigators performed the analyses independently and according to the prespecified, a priori analysis plan. All results were examined and critiqued by clinical investigators (S.I.R., M.G.), who also assisted in the interpretation and presentation of results. Thus, every step possible was taken to minimize bias. The results of this secondary analysis suggests that a mean improvement in BCSS total score with treatment approaching or exceeding 1 point represents a substantial improvement in symptoms in the COPD population. This value corresponded to ratings by both physicians and patients that the treatment was highly efficacious. The corresponding mean SGRQ total score exceeded the guideline of 8 points considered a large improvement in health status, indicating this level of symptom relief was accompanied by substantial improvements in patient functioning and well-being. Symptomatic improvements 1 point were also observed during recovery from acute exacerbations of COPD, and were accompanied by improvements in PEF and a reduction in rescue medication use. Together, these results indicate mean changes 1 point on the BCSS total CHEST / 124 / 6/ DECEMBER,

7 Figure 1. Mean BCSS total score for patients with complete data (n 713, total; n 219, mild; n 395, moderate; n 99, severe) for the pre-exacerbation period (7 days before exacerbation), exacerbation period (first 7 days of exacerbation), and postexacerbation period (first 7 days after medically confirmed resolution) by exacerbation severity. (Sample variability [SD] for the three severity groups during exacerbation: 2.18 to 2.38, mild, 2.18 to 2.44, moderate; and 2.24 to 2.64, severe). score represent a relatively dramatic improvement in symptoms for patients with COPD. That is not to say that further improvement would not be possible or desirable, but rather that treatment leading to a group-level mean change of 1 point on the BCSS total score corresponds to substantial symptomatic relief in this population. Mean improvements in BCSS total score of 0.60 to 0.70 were observed in patients for whom treatment was considered moderately effective. This change was associated with smaller yet substantial percentage improvements in symptoms, along with clinically meaningful changes in health status or HRQL. Once again, patients experienced sufficient symptomatic relief to also realize meaningful, though less dramatic, improvements in daily function and well-being. Together, these results suggest that a mean BCSS total score of or near 0.60 can be interpreted as a moderate-to-large symptomatic improvement from both clinical and empirical perspectives. A mean BCSS total score of 0.30 to 0.40 accompanied treatment considered mildly efficacious and corresponded to 6 to 7% improvement in symptoms and negligible change in HRQL. However, results from interviews with COPD patients conducted as part of a cognitive debriefing study for the BCSS suggest patients can perceive and appreciate a small improvement in symptoms, regardless of any concomitant improvement in day-to-day activities (data not shown). One could argue, therefore, that a BCSS total score 0.30 to 0.35, though small, represents clinically meaningful symptomatic relief to patients with COPD. Mean BCSS values of 0.01 to 0.12 were observed in patients for whom treatment was perceived, by physicians and patients, as ineffective. No changes in pulmonary function or health status were observed in this group. These results attest to the reproducibility of the BCSS under conditions of clinical stability. They also cast doubt on the clinical significance of any treatment in which a mean BCSS total score of 0.20 is observed. Interpretation of individual items comprising the BCSS requires further quantitative and qualitative study of symptom-specific change. However, based on the results of this and previous studies, 12 mean change scores of 0.25 to 0.50 on breathlessness, 0.15 to 0.40 on cough, and 0.10 to 0.30 on sputum could be interpreted as moderate-to-large changes, with 2188 Clinical Investigations

8 Table 4 Mean BCSS Total Scores Immediately Prior, During, and Immediately After Acute Exacerbation by Exacerbation Severity, Juxtaposed With PEF and Rescue Medication Use* Physician Rating of Exacerbation Severity BCSS Total Score PEF, ml Rescue Medication Use, Puffs/d No. Prior During After No. Prior During After No. Prior During After Overall Mean (SD) (2.15) 6.54 (2.24) 5.26 (2.15) (83.6) 238 (83) 250 (84.2) (4.2) 5.3 (6.0) 4.6 (4.2) Change 1.24 (1.74) 1.28 (1.80) 10 (22) (28.0) 0.8 (3.8) 0.7 (3.5) Change, % ES Mild Mean (SD) (2.10) 5.78 (2.19) 4.94 (2.19) (83.71) 261 (83) (85.25) (3.8) 4.0 (4.4) 3.9 (4.1) Change 1.01 (1.51) 0.84 (1.53) 9 (19) 5.36 (10.13) 0.6 (2.4) 0.1 (2.1) Change, % ES Moderate Mean (SD) (2.05) 6.72 (2.15) 5.33 (2.10) (83.92) 237 (83) (83.92) (4.0) 5.4 (4.3) 4.8 (3.9) Change 1.39 (1.77) 1.39 (1.80) (24) (27.31) 0.70 (1.9) 0.7 (2.3) Change, % ES Severe Mean (SD) (2.28) 7.50 (2.20) 5.70 (2.21) (70.67) 204 (73) (78.22) (5.3) 8.1 (11.6) 6.2 (5.9) Change 1.19 (2.03) 1.81 (2.10) 9 (23) (38.00) 1.4 (8.7) 1.9 (7.3) Change, % ES *Patients with complete data over three time periods (n 713): prior (7 days before exacerbation), during (first 7 days of examination), and after (first 7 days after medically confirmed resolution). Change, % Change, and ES are for changes from the before to during and from during to after exacerbation periods. (Mt Mb)/ b. CHEST / 124 / 6/ DECEMBER,

9 the descending values across the three symptoms consistent with the dominance of breathlessness in the selection and evaluation of treatment in this population. These values are proposed as a basis for further clinical and qualitative investigation. Results of this study also substantiate the need for observational and qualitative studies of the pattern and meaning associated with day-to-day symptom variability and the predictive value of increasing scores over time in patients with COPD. The current study showed a progressive increase in symptoms prior to medical confirmation of an exacerbation, implying a delay in seeking treatment. Unfortunately, this waiting period impedes timely intervention for acute exacerbations to reduce the severity and duration of the exacerbation. 18 The tendency for patients to tolerate increasing symptoms may also contribute to the underreporting of exacerbations described by Seemungal and colleagues. 19,20 Daily monitoring of the key symptoms of COPD may be a useful clinical tool for helping patients track the status of their disease, detect subtle yet clinically meaningful increases in symptom severity, modify their treatment or seek care, and initiate early treatment of a developing exacerbation. Consensus documents and new guidelines for the classification, treatment, and management of COPD 1 suggest symptom management should play a primary role in the treatment of stable disease. In this context, the evaluation of new treatments requires a robust quantitative method for symptom assessment. The current study indicates daily patient reports of symptom severity, using instruments such as the BCSS, are sensitive to the effects of treatment in this population, and could therefore be used to assess therapeutic interventions. Current guidelines also recognize exacerbations as therapeutic targets in COPD. Several therapies have been suggested to decrease exacerbation frequency, severity, or duration ; these studies have been hampered, however, by a lack of consensus on the definition for both exacerbation events and severity. A recent consensus panel 26 suggested tying exacerbation definition and severity assessment to healthcare utilization. While operationally convenient and relevant for health economic analyses, variations in health-care delivery systems complicate the generalizability of results obtained from studies using such definitions. Since COPD exacerbations are characterized by symptomatic worsening, an instrument such as the BCSS that provides simple and robust quantification of symptoms that can be repeated on a daily basis, may prove particularly valuable for evaluating exacerbations in patients with COPD. In summary, the purpose of this study was to establish guidelines for interpreting mean change scores in clinical trials in which the BCSS is used to evaluate symptomatic improvement in patients with COPD. A triangulation approach was used, in which changes in BCSS scores were evaluated in light of changes observed in familiar clinical and statistical indicators of improvement in this population. Based on this evaluation, a mean improvement of 1.0 on the BCSS total score is an indication that, on average, patients in a given treatment group experienced dramatic symptomatic relief with treatment; changes of 0.60 to 0.70 represent moderate-to-large symptomatic improvement; and mean changes at or near 0.35 indicate the treatment under evaluation provides small, but clinically meaningful symptom relief. It is doubtful that treatment with a group-level mean change 0.20 offers meaningful symptomatic benefit. A prospective study with a prior hypotheses addressing change in BCSS scores and other clinical indicators of improvement, along with qualitative interviews with patients and clinicians concerning the magnitude of symptomatic change with treatment, would be needed to further this tool for clinical research. Nonetheless, these results provide evidence that patient-reported diary card data can be sensitive to change in patients with COPD and may serve as valuable tools for both clinical research and as an assessment of the effect of medical and therapeutic interventions in such patients. Appendix: BCSS The BCSS was used in clinical trials as part of a patient s daily diary card. Below is a sample instruction page from the diary card. Please complete in the evening (prior to going to bed): Please enter day (Monday, Tuesday, etc.): Please record the date (day/month): How much difficulty did you have breathing today? 0 None: unaware of any difficulty 1 Mild: noticeable during strenuous activity (eg, running) 2 Moderate: noticeable during light activity (eg, bedmaking) 3 Marked: noticeable when washing or dressing 4 Severe: almost constant, present even when resting How was your cough today? 0 None: unaware of coughing 1 Rare: cough now and then 2 Occasional: less than hourly 3 Frequent: one or more times an hour 4 Almost constant: never free of cough or need to cough How much trouble was your sputum today? 0 None: unaware of any difficulty 1 Mild: rarely caused problem 2 Moderate: noticeable as a problem 3 Marked: caused a great deal of inconvenience 4 Severe: an almost constant problem For permission to use this instrument, contact Dr. Mitchell Goldman at mitchell.goldman@astrazeneca.com 2190 Clinical Investigations

10 References 1 National Heart, Lung, and Blood Institute. Global Initiative for Chronic Obstructive Lung Disease. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, Publication No. 2701A. Available from: index.html; accessed November 10, Siafakas NM, Vermeire P, Price NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): The European Respiratory Society Task Force. Eur Respir J 1995; 8: American Thoracic Society Board of Directors. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77 S120 4 COPD Guideline Group of the Standards of Care Committee of the British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52(suppl 5):S1 S28 5 Mahler DA, Faryniarz K, Tomlinson D, et al. Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease. Chest 1992; 102: Eltayara L, Becklace MR, Volta CA, et al. Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154(6 pt 1): McGavin CR, Artvinli M, Naoe H, et al. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. BMJ 1978; 2: Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: Selim AJ, Ren XS, Fincke G, et al. A symptom-based measure for the severity of chronic lung disease: results from the Veterans Health Study. Chest 1997; 111: Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation: the St. George s Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: Leidy NK, Schmier J, Jones MKC, et al. Evaluating symptoms in COPD: Validation of the Breathlessness, Cough and Sputum Scale. Respir Med 2003; 97(Suppl A):S59 S70 13 Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York, NY: McGraw-Hill, Celli B, Halpin D, Hepburn R, et al. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS). Respir Med 2003; 97(Suppl A):S35 S43 15 Laursen LC, Lindqvist A, Hepburn T, et al. The role of the novel D 2 / 2 -agonist, Viozan (sibenadet HCl), in the treatment of symptoms of COPD: results of a large-scale clinical investigation. Respir Med 2002; 97(Suppl A):S23 S33 16 Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale NJ: Lawrence Erlbaum Associates, Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: Seemungal T, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr s treatment with tiotropium: Dutch/Belgian Tiotropium Study Group. Eur Respir J 2002; 19: Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease: International COPD Study Group. Lancet 1998; 351: Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117(Suppl 2):398S 401S CHEST / 124 / 6/ DECEMBER,

C hronic obstructive pulmonary disease (COPD) is one of

C hronic obstructive pulmonary disease (COPD) is one of 589 RESPIRATORY INFECTIONS Time course of recovery of health status following an infective exacerbation of chronic bronchitis S Spencer, P W Jones for the GLOBE Study Group... Thorax 2003;58:589 593 See

More information

A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma

A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma Eur Respir J 1999; 1: 591±596 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 93-1936 A comparison of global questions versus health status questionnaires

More information

Journal of the COPD Foundation

Journal of the COPD Foundation 132 Predictors of Change in SGRQ Score Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Original Research Baseline Severity as Predictor of Change in St George s Respiratory Questionnaire

More information

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH

More information

Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire*

Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire* Original Research COPD Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire* Makiko Meguro, Mphil; Elizabeth A. Barley, PhD, CPsychol; Sally Spencer,

More information

Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale

Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale Vol. 97 (2003)(SUPPLEMENT A), $59-$70 IIIl~lllll]Ui~lll][lll l~ Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale N. K. LEIDY, I* J.

More information

Chronic obstructive pulmonary disease (COPD) is characterized

Chronic obstructive pulmonary disease (COPD) is characterized DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment

More information

Journal of the COPD Foundation. The Short-term Impact of Symptom-defined COPD Exacerbation Recovery on Health Status and Lung Function

Journal of the COPD Foundation. The Short-term Impact of Symptom-defined COPD Exacerbation Recovery on Health Status and Lung Function 27 Symptom-defined Exacerbation Recovery Impact Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Original Research The Short-term Impact of Symptom-defined COPD Exacerbation Recovery

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Minimal important difference of the transition dyspnoea index in a multinational clinical trial

Minimal important difference of the transition dyspnoea index in a multinational clinical trial Eur Respir J 2003; 21: 267 272 DOI: 10.1183/09031936.03.00068503a Printed in UK all rights reserved Copyright #ERS Journals Ltd 2003 European Respiratory Journal ISSN 0903-1936 Minimal important difference

More information

PSYCHOMETRIC ASSESSMENT OF THE CHINESE LANGUAGE VERSION OF THE ST. GEORGE S RESPIRATORY QUESTIONNAIRE IN TAIWANESE PATIENTS WITH BRONCHIAL ASTHMA

PSYCHOMETRIC ASSESSMENT OF THE CHINESE LANGUAGE VERSION OF THE ST. GEORGE S RESPIRATORY QUESTIONNAIRE IN TAIWANESE PATIENTS WITH BRONCHIAL ASTHMA St. George's Respiratory Questionnaire PSYCHOMETRIC ASSESSMENT OF THE CHINESE LANGUAGE VERSION OF THE ST. GEORGE S RESPIRATORY QUESTIONNAIRE IN TAIWANESE PATIENTS WITH BRONCHIAL ASTHMA Kwua-Yun Wang, Chi-Hue

More information

Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials

Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials Leidy et al. Respiratory Research 214, 15:124 RESEARCH Open Access Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials Nancy K Leidy

More information

The TORCH (TOwards a Revolution in COPD Health) survival study protocol

The TORCH (TOwards a Revolution in COPD Health) survival study protocol Eur Respir J 2004; 24: 206 210 DOI: 10.1183/09031936.04.00120603 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2004 European Respiratory Journal ISSN 0903-1936 LAUNCHING NEW STUDIES The

More information

UNDERSTANDING COPD MEDIA BACKGROUNDER

UNDERSTANDING COPD MEDIA BACKGROUNDER UNDERSTANDING COPD MEDIA BACKGROUNDER What is COPD? Chronic Obstructive Pulmonary Disease (COPD) also called emphysema and/or chronic obstructive bronchitis* is a preventable lung disease caused by the

More information

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease Thorax 1999;54:581 586 581 Academic Department of Respiratory Medicine, St Bartholomew s and Royal London School of Medicine and Dentistry, London Chest Hospital, London, UK EAPaul R Garrod R Garnham J

More information

Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD?

Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD? AUTHOR COPY ORIGINAL RESEARCH Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD? Kian-Chung Ong 1 Suat-Jin Lu 1 Cindy Seok-Chin Soh 2 1 Department

More information

The physiological hallmark of chronic. Tiotropium as essential maintenance therapy in COPD. M. Decramer

The physiological hallmark of chronic. Tiotropium as essential maintenance therapy in COPD. M. Decramer Eur Respir Rev 2006; 15: 99, 51 57 DOI: 10.1183/09059180.00009906 CopyrightßERSJ Ltd 2006 Tiotropium as essential maintenance therapy in COPD M. Decramer ABSTRACT: Over the past decade, several large-scale

More information

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and

More information

The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia.

The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. Rennard, Stephen I; Sin, Donald D; Tashkin, Donald P; Calverley, Peter M; Radner, Finn Published in: Annals

More information

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam

More information

roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd

roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR)

Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR) 954 Department of Respiratory Medicine, University Hospitals of Leicester, Glenfield Hospital, Leicester LE3 9QP, UK J E A Williams S J Singh L Sewell M D L Morgan Department of Clinical Epidemiology and

More information

Interpreting thresholds for a clinically significant change in health status in asthma and COPD

Interpreting thresholds for a clinically significant change in health status in asthma and COPD Eur Respir J 2002; 19: 398 404 DOI: 10.1183/09031936.02.00063702 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Interpreting thresholds for

More information

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to: Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict

More information

Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification

Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification ORIGINAL ARTICLE COPD Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification Paul W. Jones 1, Lukasz Adamek 2, Gilbert Nadeau 2 and Norbert Banik 3 Affiliations:

More information

Patient reported outcomes in respiratory diseases; How to assess clinical success in COPD

Patient reported outcomes in respiratory diseases; How to assess clinical success in COPD Patient reported outcomes in respiratory diseases; How to assess clinical success in COPD Thys van der Molen, University of Groningen, Department of General Practice, The Netherlands Mr Valette Smoking

More information

COPD is a progressive disorder leading to increasing

COPD is a progressive disorder leading to increasing Improvement in Exercise Tolerance With the Combination of Tiotropium and Pulmonary Rehabilitation in Patients With COPD* Richard Casaburi, MD, PhD, FCCP; David Kukafka, MD, FCCP; Christopher B. Cooper,

More information

รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น

รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines

More information

Comparing COPD Treatment: Nebulizer, Metered Dose Inhaler, and Concomitant Therapy

Comparing COPD Treatment: Nebulizer, Metered Dose Inhaler, and Concomitant Therapy The American Journal of Medicine (2007) 120, 435-441 CLINICAL RESEARCH STUDY Comparing COPD Treatment:, Metered Dose, and Concomitant Therapy Donald P. Tashkin, MD, a Gerald L. Klein, MD, b,c Shoshana

More information

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved. Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights

More information

Health-related quality of life is associated with COPD severity: a comparison between the GOLD staging and the BODE index

Health-related quality of life is associated with COPD severity: a comparison between the GOLD staging and the BODE index Chronic Respiratory Disease 2009; 6: 75 80 http://crd.sagepub.com ORIGINAL PAPER Health-related quality of life is associated with COPD severity: a comparison between the GOLD staging and the BODE index

More information

Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]

Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For

More information

Longitudinal deteriorations in patient reported outcomes in patients with COPD

Longitudinal deteriorations in patient reported outcomes in patients with COPD Respiratory Medicine (2007) 101, 146 153 Longitudinal deteriorations in patient reported outcomes in patients with COPD Toru Oga a,, Koichi Nishimura b, Mitsuhiro Tsukino c, Susumu Sato a, Takashi Hajiro

More information

Validity and Reliability of CAT and Dyspnea-12 in Bronchiectasis and Tuberculous Destroyed Lung

Validity and Reliability of CAT and Dyspnea-12 in Bronchiectasis and Tuberculous Destroyed Lung http://dx.doi.org/10.4046/trd.2012.72.6.467 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2012;72:467-474 CopyrightC2012. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights

More information

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published

More information

Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited

Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited Eur Respir J 28; 32: 17 24 DOI: 1.1183/931936.16157 CopyrightßERS Journals Ltd 28 PERSPECTIVE Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited O.N. Keene*, P.M.A. Calverley

More information

Roflumilast for the management of severe chronic obstructive pulmonary disease

Roflumilast for the management of severe chronic obstructive pulmonary disease Roflumilast for the management of severe chronic obstructive pulmonary disease Issued: January 2012 www.nice.org.uk/ta244 NHS Evidence has accredited the process used by the Centre for Health Technology

More information

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies

More information

Roflumilast (Daxas) for chronic obstructive pulmonary disease

Roflumilast (Daxas) for chronic obstructive pulmonary disease Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended

More information

Roflumilast for the management of severe chronic obstructive pulmonary disease

Roflumilast for the management of severe chronic obstructive pulmonary disease Roflumilast for the management of severe chronic obstructive pulmonary disease Issued: January 2012 guidance.nice.org.uk/ta244 NICE has accredited the process used by the Centre for Health Technology Evaluation

More information

Disease progression in COPD:

Disease progression in COPD: Disease progression in COPD: What is it? How should it be measured? Can it be modified? Professor Paul Jones MD, PhD, FERS Emeritus Professor of Respiratory Medicine; St George s, University of London

More information

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease 0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find

More information

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary

More information

Characterisation and impact of reported and unreported exacerbations: results from ATTAIN

Characterisation and impact of reported and unreported exacerbations: results from ATTAIN ORIGINAL ARTICLE COPD Characterisation and impact of reported and unreported exacerbations: results from ATTAIN Paul W. Jones 1, Rosa Lamarca 2, Ferran Chuecos 2, Dave Singh 3, Alvar Agustí 4,5, Eric D.

More information

Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement

Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix JF Herth, Chau Thach, Robert Fogel, Petter Olsson,

More information

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. 1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 19 February 2009 Doc. Ref. EMEA/CHMP/EWP/8197/2009 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CONCEPT

More information

exacerbation has greater impact on functional status than frequency of exacerbation episodes.

exacerbation has greater impact on functional status than frequency of exacerbation episodes. Original Article Singapore Med J 2011, 52(12) 894 Changes in the BODE index, exacerbation duration and hospitalisation in a cohort of COPD patients Bu X N, Yang T, Thompson M A, Hutchinson A F, Irving

More information

To describe the impact of COPD exacerbations and the importance of the frequent exacerbator phenotype.

To describe the impact of COPD exacerbations and the importance of the frequent exacerbator phenotype. Educational aims To describe the impact of COPD exacerbations and the importance of the frequent exacerbator phenotype. To describe the spectrum of pharmacological and non-pharmacological interventions

More information

umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline

umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Self-Management Plan for COPD

Self-Management Plan for COPD Self-Management Plan for COPD This is your personal management plan. The aim of this plan is to help you have better control of your chronic obstructive pulmonary disease (COPD). It will enable you to

More information

SGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life

SGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life SUPPLEMENTARY MATERIAL e-table 1: Outcomes studied in present analysis. Outcome Abbreviation Definition Nature of data, direction indicating adverse effect (continuous only) Clinical outcomes- subjective

More information

Chronic Obstructive Pulmonary Diseases:

Chronic Obstructive Pulmonary Diseases: 150 Socioeconomic Status and Treatment Response in COPD Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Original Research Socioeconomic Status as a Determinant of Health Status Treatment

More information

Decramer 2014 a &b [21]

Decramer 2014 a &b [21] Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively

More information

COPD in primary care: reminder and update

COPD in primary care: reminder and update COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice

More information

A comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD

A comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD RESPIRATORY MEDICINE (2001) 95, 71 77 doi:10.1053/rmed.2000.0976, available online at http://www.idealibrary.com on A comparison of three disease-specific and two generic health-status measures to evaluate

More information

Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore $

Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore $ Respiratory Medicine (2006) 100, 2190 2196 Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore $ Kang-Hoe

More information

Acute exacerbations of chronic obstructive

Acute exacerbations of chronic obstructive Eur Respir Rev 2005; 14: 95, 78 82 DOI: 10.1183/09059180.05.00009507 CopyrightßERSJ Ltd 2005 Modulation of airway inflammation to prevent exacerbations of COPD M. Solèr ABSTRACT: Exacerbations of chronic

More information

Guidance for Industry Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment

Guidance for Industry Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment Guidance for Industry Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions

More information

Asthma Tutorial. Trainer MRW. Consider the two scenarios, make an attempt at the questions, what guidance have you used?

Asthma Tutorial. Trainer MRW. Consider the two scenarios, make an attempt at the questions, what guidance have you used? Registrar: LG PR RS Topic Asthma and COPD Asthma Tutorial Trainer MRW Date of Tutorial 18 th Jan 2007 Objectives of the tutorial How to diagnose What investigations and when Treatment guidelines QoF Criteria

More information

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation : The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease

More information

COPD. Breathing Made Easier

COPD. Breathing Made Easier COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought

More information

SHORT COMMUNICATION. Abstract. Kevin R. Murphy, 1 Tom Uryniak, 2 Ubaldo J. Martin 2 and James Zangrilli 2

SHORT COMMUNICATION. Abstract. Kevin R. Murphy, 1 Tom Uryniak, 2 Ubaldo J. Martin 2 and James Zangrilli 2 SHORT COMMUNICATION Drugs R D 212; 12 (1): 9-14 1179-691/12/1-9 ª 212 Murphy et al., publisher and licensee Adis Data Information BV. This is an open access article published under the terms of the Creative

More information

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting

More information

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%

More information

Dual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.

Dual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS. DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms

More information

COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases

COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases «If you test one smoker with cough every day You will diagnose

More information

Commissioning for Better Outcomes in COPD

Commissioning for Better Outcomes in COPD Commissioning for Better Outcomes in COPD Dr Matt Kearney Primary Care & Public Health Advisor Respiratory Programme, Department of Health General Practitioner, Runcorn November 2011 What are the Commissioning

More information

Chronic obstructive pulmonary disease. Development and first validation of the COPD Assessment Test

Chronic obstructive pulmonary disease. Development and first validation of the COPD Assessment Test Eur Respir J 2009; 34: 648 654 DOI: 10.1183/09031936.00102509 CopyrightßERS Journals Ltd 2009 Development and first validation of the COPD Assessment Test P.W. Jones*, G. Harding #, P. Berry ", I. Wiklund

More information

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,

More information

VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide

VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical

More information

Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance

Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance Eur Respir Rev 2006; 15: 99, 37 41 DOI: 10.1183/09059180.00009903 CopyrightßERSJ Ltd 2006 Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance D.E. O Donnell ABSTRACT: The

More information

Shaping a Dynamic Future in Respiratory Practice. #DFResp

Shaping a Dynamic Future in Respiratory Practice. #DFResp Shaping a Dynamic Future in Respiratory Practice #DFResp www.dynamicfuture.co.uk Inhaled Therapy in COPD: Past, Present and Future Richard Russell Chest Physician West Hampshire Integrated Respiratory

More information

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong

More information

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause

More information

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Guideline for the Diagnosis and Management of COPD

Guideline for the Diagnosis and Management of COPD Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially

More information

Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis

Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis Respiratory Medicine (2010) 104, 534e541 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed COPD Responsiveness of the cough and sputum assessment questionnaire in exacerbations

More information

Over the last several years various national and

Over the last several years various national and Recommendations for the Management of COPD* Gary T. Ferguson, MD, FCCP Three sets of guidelines for the management of COPD that are widely recognized (from the European Respiratory Society [ERS], American

More information

This is a cross-sectional analysis of the National Health and Nutrition Examination

This is a cross-sectional analysis of the National Health and Nutrition Examination SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is

More information

Is there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions?

Is there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions? Respiratory Medicine (2004) 98, 178 183 Is there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions? Maria Tsoumakidou, Nikolaos Tzanakis,

More information

Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD

Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD Send Orders of Reprints at bspsaif@emirates.net.ae 150 The Open Respiratory Medicine Journal, 2012, 6, 150-154 Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD Charlotte Suppli

More information

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1 58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family

More information

glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.

glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed

More information

The beneficial effects of ICS in COPD

The beneficial effects of ICS in COPD BIOLOGY AND HEALTH Journal website: www.biologyandhealth.com Narrative review The beneficial effects of ICS in COPD Stacha Reumers Stacha Reumers I6111431 Maastricht University Faculty of Health, Medicine

More information

CEDAC FINAL RECOMMENDATION

CEDAC FINAL RECOMMENDATION CEDAC FINAL RECOMMENDATION ROFLUMILAST (Daxas Nycomed Canada Inc.) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that

More information

Comparison of respiratory health-related quality of life in patients with intractable breathlessness due to advanced cancer or advanced COPD

Comparison of respiratory health-related quality of life in patients with intractable breathlessness due to advanced cancer or advanced COPD Comparison of respiratory health-related quality of life in patients with intractable breathlessness due to advanced cancer or advanced COPD Shagayegh Javadzadeh, BA (Hons) Cantab University of School

More information

Title: Objective measurement of cough frequency during COPD exacerbation convalescence

Title: Objective measurement of cough frequency during COPD exacerbation convalescence The final publication is available at Springer via http://dx.doi.org/10.1007/s00408-015-9782-y Title: Objective measurement of cough frequency during COPD exacerbation convalescence Michael G Crooks 1,

More information

James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD

James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD Therapeutic Effect of Zafirlukast as Monotherapy in Steroid-Naive Patients With Severe Persistent Asthma* James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren,

More information

Acute Exacerbations of COPD in Subjects Completing Pulmonary Rehabilitation

Acute Exacerbations of COPD in Subjects Completing Pulmonary Rehabilitation Acute Exacerbations of COPD in Subjects Completing Pulmonary Rehabilitation S. Jocelyn Carr, Roger S. Goldstein and Dina Brooks Chest 2007;132;127-134; Prepublished online May 2, 2007; DOI 10.1378/chest.07-0269

More information

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach

More information

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe

More information

Comparison of patient-reported outcomes during acute exacerbations of chronic obstructive pulmonary disease

Comparison of patient-reported outcomes during acute exacerbations of chronic obstructive pulmonary disease To cite: Nishimura K, Nakamura S, Kusunose M, et al. Comparison of patientreported outcomes during acute exacerbations of chronic obstructive pulmonary disease. BMJ Open Resp Res 2018;5:e000305. doi:10.1136/

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Short-burst oxygen immediately before and after exercise is ineffective in nonhypoxic COPD patients

Short-burst oxygen immediately before and after exercise is ineffective in nonhypoxic COPD patients Eur Respir J 2003; 22: 584 588 DOI: 10.1183/09031936.03.00027603a Printed in UK all rights reserved Copyright #ERS Journals Ltd 2003 European Respiratory Journal ISSN 0903-1936 CLINICAL FORUM Short-burst

More information

Pulmonary rehabilitation (PR) is an important

Pulmonary rehabilitation (PR) is an important Power of Outcome Measurements to Detect Clinically Significant Changes in Pulmonary Rehabilitation of Patients With COPD* Juan Pablo de Torres, MD; Victor Pinto-Plata, MD; Edward Ingenito, MD; Peter Bagley,

More information

Cigarette Smoking and Lung Obstruction Among Adults Aged 40 79: United States,

Cigarette Smoking and Lung Obstruction Among Adults Aged 40 79: United States, NCHS Data Brief No. 8 January 25 Cigarette Smoking and Lung Obstruction Among Adults Aged 4 79: United States, 27 22 Ryne Paulose-Ram, Ph.D., M.A.; Timothy Tilert, B.S.; Charles F. Dillon, M.D., Ph.D.;

More information